Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies

K. Itoh, C. M. Balch, J. L. Murray, D. R. Parkinson, Avi Markowitz, M. Talpaz, K. Lee, A. A. Zukiwski, M. I. Ross, S. S. Legha, K. Hayakawa, M. A. Salmeron, L. B. Augustus

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

    Original languageEnglish (US)
    Pages (from-to)647-654
    Number of pages8
    JournalIn Vivo
    Volume5
    Issue number6
    StatePublished - 1991

    Fingerprint

    Tumor-Infiltrating Lymphocytes
    Biological Therapy
    Lymphocytes
    Interleukin-2
    Tumors
    Melanoma
    Cells
    Cytotoxicity
    Cell culture
    Neoplasms
    Therapeutics
    Adoptive Transfer

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Itoh, K., Balch, C. M., Murray, J. L., Parkinson, D. R., Markowitz, A., Talpaz, M., ... Augustus, L. B. (1991). Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo, 5(6), 647-654.

    Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. / Itoh, K.; Balch, C. M.; Murray, J. L.; Parkinson, D. R.; Markowitz, Avi; Talpaz, M.; Lee, K.; Zukiwski, A. A.; Ross, M. I.; Legha, S. S.; Hayakawa, K.; Salmeron, M. A.; Augustus, L. B.

    In: In Vivo, Vol. 5, No. 6, 1991, p. 647-654.

    Research output: Contribution to journalArticle

    Itoh, K, Balch, CM, Murray, JL, Parkinson, DR, Markowitz, A, Talpaz, M, Lee, K, Zukiwski, AA, Ross, MI, Legha, SS, Hayakawa, K, Salmeron, MA & Augustus, LB 1991, 'Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies', In Vivo, vol. 5, no. 6, pp. 647-654.
    Itoh K, Balch CM, Murray JL, Parkinson DR, Markowitz A, Talpaz M et al. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo. 1991;5(6):647-654.
    Itoh, K. ; Balch, C. M. ; Murray, J. L. ; Parkinson, D. R. ; Markowitz, Avi ; Talpaz, M. ; Lee, K. ; Zukiwski, A. A. ; Ross, M. I. ; Legha, S. S. ; Hayakawa, K. ; Salmeron, M. A. ; Augustus, L. B. / Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In: In Vivo. 1991 ; Vol. 5, No. 6. pp. 647-654.
    @article{954968dde7e740e8bd96c199066d272a,
    title = "Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies",
    abstract = "Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.",
    author = "K. Itoh and Balch, {C. M.} and Murray, {J. L.} and Parkinson, {D. R.} and Avi Markowitz and M. Talpaz and K. Lee and Zukiwski, {A. A.} and Ross, {M. I.} and Legha, {S. S.} and K. Hayakawa and Salmeron, {M. A.} and Augustus, {L. B.}",
    year = "1991",
    language = "English (US)",
    volume = "5",
    pages = "647--654",
    journal = "In Vivo",
    issn = "0258-851X",
    publisher = "International Institute of Anticancer Research",
    number = "6",

    }

    TY - JOUR

    T1 - Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies

    AU - Itoh, K.

    AU - Balch, C. M.

    AU - Murray, J. L.

    AU - Parkinson, D. R.

    AU - Markowitz, Avi

    AU - Talpaz, M.

    AU - Lee, K.

    AU - Zukiwski, A. A.

    AU - Ross, M. I.

    AU - Legha, S. S.

    AU - Hayakawa, K.

    AU - Salmeron, M. A.

    AU - Augustus, L. B.

    PY - 1991

    Y1 - 1991

    N2 - Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

    AB - Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

    UR - http://www.scopus.com/inward/record.url?scp=0026321309&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0026321309&partnerID=8YFLogxK

    M3 - Article

    VL - 5

    SP - 647

    EP - 654

    JO - In Vivo

    JF - In Vivo

    SN - 0258-851X

    IS - 6

    ER -